USA flag logo/image

An Official Website of the United States Government

Camptothecin Analogs for Cancer Therapy

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
85409 		Program Year/Program:
2007 / SBIR
Agency Tracking Number:
CA125871 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
DEKK-TEC, INC.
725 TOPAZ STREET NEW ORLEANS, LA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2007
Title: Camptothecin Analogs for Cancer Therapy
Agency: HHS
Contract: 1R43CA125871-01A1
Award Amount: $158,895.00
 

Abstract:

DESCRIPTION (provided by applicant): 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, are novel camptothecins that were designed to be used in the treatment of childhood neuroblastoma. These CPT analogs are lactones that have increased activity in acidic hypoxia tissues, characteristic of fast growing cancers that characteristically out grow their blood supply. Preliminary in vitro and in vivo studies are presented to support documenting other tumor models that might be more se nsitive. The specific objectives of this Phase I study will be to: 1. Synthesize 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, BACPTDP in 100 g quantities - sufficient for preclinical studies. 2. Verify the anticancer profi le in xenograft studies. 3. Develop the analytical assays required to document purity and stability and develop/validate protocols for pharmacokinetic studies. Upon completion of these studies a Phase II application will be submitted for completion of prec linical studies required for IND submission. BACPT and BACPTDP are novel camptothecins that were originally designed at Duke University to be used in the treatment of childhood neuroblastoma. Subsequently, DEKK-TEC has partnered with Duke and Research Tria ngle Institute (RTI) to complete the pre-clinical development, prepare the IND and ready the products for a Phase 1 clinical trial. Prior to the latter, DEKK-TEC proposes screening the analogs in a wide spectrum of tumor models to insure the best cancer ap plications for the products.

Principal Investigator:

Lee R. Morgan
5045836135
LRM1579@AOL.COM

Business Contact:

Morgan
lrm1579@aol.com
Small Business Information at Submission:

DEKK-TEC, INC.
725 TOPAZ STREET NEW ORLEANS, LA 70124

EIN/Tax ID: 720976996
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No